ADIL - Adial Pharmaceuticals Inc
IEX Last Trade
0.9738
-0.015 -1.561%
Share volume: 78,749
Last Updated: Fri 30 Aug 2024 09:59:31 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$0.99
-0.02
-1.54%
Fundamental analysis
29%
Profitability
30%
Dept financing
16%
Liquidity
50%
Performance
25%
Performance
5 Days
1.34%
1 Month
-1.90%
3 Months
-32.34%
6 Months
-39.44%
1 Year
-72.98%
2 Year
-92.73%
Key data
Stock price
$0.97
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.76 - $4.36
52 WEEK CHANGE
-$0.77
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website: adialpharma.com
Employees: 6
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: adialpharma.com
Employees: 6
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
adial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.
Recent news